Montag A & Associates Inc. cut its position in Novartis AG (NYSE:NVS) by 2.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,680 shares of the company’s stock after selling 228 shares during the quarter. Montag A & Associates Inc.’s holdings in Novartis were worth $738,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of NVS. Truvestments Capital LLC bought a new position in Novartis in the first quarter valued at about $25,000. Canton Hathaway LLC acquired a new stake in shares of Novartis in the first quarter valued at about $26,000. AlphaMark Advisors LLC acquired a new stake in shares of Novartis in the fourth quarter valued at about $30,000. Financial Gravity Wealth Inc. acquired a new stake in shares of Novartis in the first quarter valued at about $33,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in shares of Novartis in the fourth quarter valued at about $35,000. Hedge funds and other institutional investors own 11.72% of the company’s stock.
Shares of Novartis stock opened at $82.77 on Tuesday. The company has a quick ratio of 0.83, a current ratio of 0.93 and a debt-to-equity ratio of 0.48. Novartis AG has a 52 week low of $63.60 and a 52 week high of $85.08. The company has a market capitalization of $191.20 billion, a price-to-earnings ratio of 16.26, a PEG ratio of 2.00 and a beta of 0.66.
Novartis (NYSE:NVS) last announced its quarterly earnings data on Wednesday, April 24th. The company reported $1.21 EPS for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.10. Novartis had a return on equity of 16.75% and a net margin of 24.55%. The firm had revenue of $11.11 billion during the quarter, compared to analysts’ expectations of $11.76 billion. During the same quarter last year, the firm posted $1.28 earnings per share. The company’s revenue for the quarter was up 1.7% compared to the same quarter last year. As a group, research analysts predict that Novartis AG will post 4.95 EPS for the current year.
NVS has been the subject of several recent research reports. JPMorgan Chase & Co. reissued a “sell” rating on shares of Novartis in a research note on Wednesday, January 16th. Liberum Capital raised Novartis from a “hold” rating to a “buy” rating in a research note on Thursday, April 25th. Morgan Stanley cut Novartis from an “equal weight” rating to an “underweight” rating and increased their price target for the company from $82.50 to $82.52 in a research note on Wednesday, April 10th. Guggenheim raised Novartis from a “neutral” rating to a “buy” rating and set a $79.16 price target for the company in a research note on Wednesday, April 24th. Finally, Zacks Investment Research cut Novartis from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 11th. Five research analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $87.57.
TRADEMARK VIOLATION WARNING: This piece of content was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.thelincolnianonline.com/2019/05/07/montag-a-associates-inc-reduces-holdings-in-novartis-ag-nvs.html.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
See Also: How is inflation measured?
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.